OARSI 2016: Invossa (TissueGene-C) gene therapy beneficial in knee OA vs. placebo
How to Cite
OrthoEvidence. OARSI 2016: Invossa (TissueGene-C) gene therapy beneficial in knee OA vs. placebo . ACE Report. 2016;5(4):46. Available from: https://myorthoevidene.com/AceReport/Report/8849
Invossatm(tissuegene-c) in patients with osteoarthritis: a phase III trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
156 patients with knee osteoarthritis were included in this study and randomized to receive a single injection of either Invossa (TissueGene-C) gene therapy, containing non-transformed and transduced chondrocytes, or saline. The study was conducted in order to determine if the gene therapy was effective in improving cartilage integrity via assessing clinical outcomes at 1 year. The findings of thi...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE